Sponsored by
This opens up a new way to deliver drugs!
This should be a key endpoint for clinical trials for glioblastomas. In this study, only 18% of the patients went back to work after surgery, radiation and Temodar. Out of these who did go back to work, most were not able to resume full time work. Only about 8 out of the 125 patients were able to return to work full time. Some of the new experimental treatments such as DCVAX and Tocagen not only had some long term survivors, but had people working full time in high level jobs 5+ years after diagnosis. That is really what we want to see, even more than merely "surviving".
See my editorial under the link to the full text of the article! This is a major breakthrough and must read article!
This is a CAR-T cell trial. It is accepting children with any type of recurrent brain tumor that expresses the HER-2 receptor.
This is an exciting project that could quickly lead to a new clinical trial for DIPG!
This is the first proof that convection enhanced delivery into the brain of a kid with DIPG is safe. There is no talk about the effectiveness of the treatment - this is just the first step - to show it is possible. Next step is to try to see which drugs are best.
This new version of the gamma knife doesn't require a frame screwed into the head any more!
We will be having a webinar with Dr Schulder in a few weeks to discuss this new version of the gamma knife!
This is an interesting combination. Will keep an eye on it. BTW: Northwell Health (Northshore Medical Center) on Long Island, NY just got the new version of the gamma knife.
A big thank you to our amazing volunteers and participants in the National Walk To End Brain Tumors! These projects are going to make a difference fast!
There is a huge unmet need in this area. Hope it works well it trials.
This suggests that LITT is safe in the posterior fossa area. It appears relatively safe and may be another option for treatment of tumors in this difficult location
Returning to work after multimodal treatment in glioblastoma patients. This is one of the most important outcome of brain tumor treatments. It should be considered an important primary endpoint for clinical trials: what % of patients are able to work full time at the level of their previous job at 1,2,3 year point? What % of patients can work at least part time at any job at 1,2,3 years. This is important because for the first time, we are seeing long term survivors of GBMs who can actually work full time at high level jobs, many years down the line. Even if a treatment only improves median survival by a small amount, but allows those who do survive to engage in meaningful work - that is a breakthrough. For example, many years ago there were reports of a high % of long term survivors with intense radiation. However, it caused so much damage that most survivors were bedridden for the rest of their lives. More recently, with DC-Vax, ICT-107, Toca 511 / Toca FC, and others, we see some long term survivors who are functioning at the highest level - executive jobs, having families, driving and enjoying life. That is what we strive for. So it should be a formal endpoint!
Let us know what you think of this format, and if you have ideas for speakers or topics for future webinars!
This is too early to say if it helps or not, but is another treatment that is available if you have the right target.
This is a big step forward! I am now working on how to use this to the advantage of brain tumor patients. If anyone wants to try to get a drug through this pathway, please join our online support group at https://virtualtrials.com/braintumor-treatments.cfm and discuss it there!
Great concept. Probably wrong drug but they are working on it. Maybe they should try 06bg
Just a reminder that it is tonight! Please join us!
This is only 1 case report but it shows great results using an old drug in a new way.
This is a new way to get drugs to the tumor!
